Biohaven Pharmaceutical Holding Company Ltd.
BHVN$2.24B
Mid CapNASDAQPharmaceutical Preparations🇺🇸North AmericaNEW HAVEN256 employees
Drugs in Pipeline
7
Phase 3 Programs
5
Upcoming Catalysts
4
Next Catalyst
May 15, 2026
9wMarket Overview
Stock performance and key metrics
BHVN News
Catalyst Timeline
4 upcoming, 1 past
Drug Pipeline
BHV-7000
Bipolar Disorder
Taldefgrobep Alfa
Obesity
BHV-8000
Parkinson Disease
Verdiperstat
Multiple System Atrophy
troriluzole
Spinocerebellar Ataxias
BHV-1510
Solid Tumor
BHV-2100
Migraine
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
BHV-7000 | Phase 3 | Bipolar Disorder | - | - |
Taldefgrobep Alfa | Phase 3 | Obesity | - | - |
BHV-8000 | Phase 3 | Parkinson Disease | - | - |
Verdiperstat | Phase 3 | Multiple System Atrophy | - | - |
troriluzole | Phase 3 | Spinocerebellar Ataxias | - | - |
BHV-1510 | Phase 2 | Solid Tumor | - | - |
BHV-2100 | Phase 2 | Migraine | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply